Search
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021. … The approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible
Ciclesonide
go.drugbank.com/drugs/DB01410ApprovedInvestigationalCiclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Categories: Agents to Treat Airway DiseaseGlatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate exhibits several immunomodulatory effects and reduces the relapse rate of relapsing-remitting multiple sclerosis (RRMS) by 30%.
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnSynthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis.
Promethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigationalPromethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. … [A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N,N,α-trimethyl-10H-phenothiazine-10-ethanamine, N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamineMethoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnIf so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular
Efalizumab
go.drugbank.com/drugs/DB00095ApprovedWithdrawnHumanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. … It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]
Oxyphenbutazone
go.drugbank.com/drugs/DB03585ApprovedWithdrawnOxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]
Garadacimab
go.drugbank.com/drugs/DB15629Approved[A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53303,L53283] It is the first inhibitor of factor XIIa to receive market approval.[L53303]